Need professional-grade analysis? Visit stockanalysis.com
$32.18M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Jasper Therapeutics Inc (JSPR) Price Performance
Jasper Therapeutics Inc (JSPR) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $1.15, down 6.50% from the previous close.
Over the past year, JSPR has traded between a low of $1.14 and a high of $6.82. The stock has lost 75.4% over this period. It is currently 83.1% below its 52-week high.
Jasper Therapeutics Inc has a market capitalization of $32.18M.
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Company Info
- Sector
- Healthcare
- Industry
- Biological Products
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- $-90,511,000
- Profit Margin
- N/A
- EPS (TTM)
- -5.82
- Book Value
- 0.41
Technical Indicators
- 52 Week High
- $7.19
- 52 Week Low
- $1.11
- 50 Day MA
- $1.46
- 200 Day MA
- $2.63
- Beta
- 3.12
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -0.48
- Price/Sales
- N/A
- Price/Book
- 2.78
- Enterprise Value
- $-17,014,356